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At discharge, the PA group had a higher median   FIM com-
pared with non-PA patients (16 vs. 9; p = 0.01). None of the 
PA patients but 5 (3.3%) of the non-PA patients had died. 
 Conclusion: PA of stroke rehabilitation was used frequently. 
The absence of safety concerns suggests that there is scope 
for benefit from PA in stroke rehabilitation. A large random-
ized controlled trial seems feasible and ethically justified. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Based on theoretical considerations of brain plasticity 
and experimental studies  [1, 2] pharmacological augmen-
tation (PA) of stroke rehabilitation might be reasonable. 
Indeed, some clinical studies showed a beneficial effect 
with different agents  [3–9] while others did not  [10–15] . 
Thus, the clinical evidence of benefit of this treatment 
approach is weak, as most of the aforementioned studies 
are limited by small sample sizes and narrow inclusion 
criteria. In addition, according to meta-analyses across 
several studies, there were some concerns about safety of 
some agents (i.e. piracetam  [16] and amphetamines  [17, 
18] ). More research is necessary  [16] . However, prior to 
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 Abstract 
 Background: Based on experimental studies, pharmacolog-
ical augmentation (PA) of stroke rehabilitation might be rea-
sonable. Whether PA is beneficial in clinical practice is un-
clear.  Methods: We performed an observational study on 
the use of PA in addition to regular rehabilitative therapies 
in a stroke rehabilitation unit. Over 20 months, we system-
atically observed (1) the utilization rate of PA, (2) possible ad-
verse events, and (3) the functional outcome of patients with 
versus without PA (non-PA). The primary outcome variable 
was the increase in abilities in activities of daily living during 
in-hospital rehabilitation as quantified by the delta ‘func-
tional independence measure’ (FIM).  Results: Ninety-seven 
of 249 (39%) patients had PA.  L -Dopa was used in 63 (65%), 
acetylcholinesterase inhibitors in 33 (34%), and selective se-
rotonin reuptake inhibitors in 31 (32%) PA patients. In 11 
(11%) patients, PA was associated with delirium (n = 4), gas-
trointestinal symptoms (n = 4), electrolyte disorders (n = 2), 
or incontinence (n = 1). All adverse events were temporary. 
PA patients did not differ from non-PA patients in age (74 vs. 
73 years; p = 0.62), gender ratio, and stroke type (ischemia 85 
vs. 82%; p = 0.49). However, compared with non-PA patients, 
PA patients were more severely affected (median NIH Stroke 
Scale Score 7 vs. 4; p  ! 0.001; median FIM 58 vs. 85; p = 0.01). 
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the design and implementation of large-scale controlled 
clinical trials, estimates about the size of the population 
of potential candidates for PA and information about the 
safety of agents to be used for PA are important.
 With these considerations in mind, we performed a 
single-center prospective study on the use of PA in addi-
tion to regular rehabilitative therapies in a stroke reha-
bilitation unit. We systematically observed (1) the utiliza-
tion rate of PA, (2) possible adverse events, and (3) the 
functional outcome of patients with versus without PA.
 Methods 
 Setting and Study Objectives 
 In January 2008, we designed an observational, single-center 
study covering all patients consecutively admitted for neurologi-
cal rehabilitation after acute ischemic or hemorrhagic stroke dur-
ing 20 months (March 1, 2008 to October 31, 2009). The neuro-
logical rehabilitation unit is located in a large community geriat-
ric center and is co-led by a geriatrician and a neurologist. The 
rehabilitation unit provides stroke rehabilitation for all inhabit-
ants of the canton Basel City, Switzerland (37.1 km 2 ; 188,015 in-
habitants; census 2002). It is part of the organized stroke care in 
Basel  [19] and closely connected to the Stroke Unit of the Univer-
sity Hospital of Basel by a defined ‘stroke pathway’. In accordance 
with this pathway patients were admitted for rehabilitation what-
ever their age  [20] . For quality assessment the rehabilitation unit 
uses a prospective database containing variables relevant to deter-
mine the outcome of rehabilitation after stroke  [20] , which was 
used for this study, too. 
 The main objectives of the current study were (1) to determine 
the utilization rate of PA, (2) to record possible adverse events of 
PA, and (3) to compare the functional outcome of patients with 
PA (i.e. the PA group) versus those without PA (i.e. non-PA group). 
 For the current study PA was defined as the use of one of the 
following agents exclusively with the idea to enhance rehabilita-
tion and in the absence of an established indication for their use. 
The list of agents potentially useful for PA was derived from the 
literature [overview in  16, 21, 22 ]. It included agents with the 
(stable) daily dosage (i.e. after the titration period) as follows:  L -
dopa  [3, 4, 11] (levodopa 100 mg b.i.d.; i.e. 30 min before break-
fast and before lunch), dopamine agonists  [5] (ropinirol 1 mg 
t.i.d.), selective serotonin reuptake inhibitors (SSRI)  [23, 24] 
(citalopram 20 mg q.d., alternatively escitalopram 10 mg q.d.), 
selective serotonin noradrenaline reuptake inhibitors (SNRI) 
 [25] (reboxetine 3 mg b.i.d.), acetylcholinesterase inhibitors  [6, 
7] (donepezil 5 mg q.d.), modafinil  [26, 27] (100 mg/day), meth-
ylphenidate  [9] (20 mg/day), and memantine  [28] (20 mg/day). 
D-amphetamines were not considered because they were not 
available.
 The decision to use PA and the choice of the agent in individ-
ual patients were made by consensus of the treating stroke neu-
rologist (S.T.E.) and the leading geriatrician (M.F.) and required 
the consent of patients or relatives. The following rules were es-
tablished to determine agents for PA for individual patients. If the 
emphasis of PA of rehabilitation was placed on paresis with or 
without cortical signs,  L -dopa was chosen  [3, 4, 11] . If aphasia with 
or without memory deficits was focused on, acetylcholinesterase 
inhibitors  [6] were preferred. SSRI and SNRI were used for the 
augmentation of low impulse or alertness. Methlyphenidate  [9] , 
dopamine agonists  [5] , and modafinil were exclusively adminis-
tered to younger patients. These rules were adapted individually 
taking into account each patient’s individual situation and condi-
tion including laboratory findings, previous experiences with 
agents, comorbidity and the willingness to take certain agents. 
Treatment duration was 4 weeks or until discharge (whatever oc-
curred first). A second agent could replace the first agent (1) after 
4 weeks or (2) if patients were willing to continue PA treatment 
after a reversible adverse reaction to the first agent. PA was used 
in addition to regular rehabilitative therapies.
 During weekly ward rounds by the stroke neurologist and the 
leading geriatrician, the patients’ status was reviewed for adverse 
events possibly related to PA (i.e. possible adverse events) in the 
judgment of at least one of the two physicians. In case of possible 
adverse events, PA was stopped immediately, and the event was 
recorded in the database.
 The predefined primary outcome measure was the increase in 
abilities in activities of daily living during in-hospital rehabilita-
tion as measured with the ‘functional independence measure’ 
(FIM)  [29] . The FIM is an 18-item assessment tool with a 7-point 
ordinal scale for each item and 2 main subscores (motor and cog-
nitive) as well as 6 minor subscores (self-care, continence, trans-
fers, locomotion, communication and social cognition)  [29] . FIM 
scorings were made by consensus in the interdisciplinary team 
within 72 h after the patients’ entry (i.e. FIM at entry). It was re-
peated before discharge (FIM at discharge).   FIM was defined as 
FIM at discharge minus FIM at entry in the rehabilitation unit. 
The secondary outcome measure was the FIM efficacy, which 
takes into account the difference in the maximally achievable 
FIM gain. The FIM efficacy = [  FIM/(126 – FIM at entry)]  ! 100. 
 The following baseline variables were derived from the pro-
spective database: age, gender, type of stroke (ischemic vs. hemor-
rhagic), NIH stroke scale score at entry, FIM at entry, FIM at dis-
charge, vascular risk factors, length of stay in the rehabilitation 
unit, death during in-hospital rehabilitation, and discharge des-
tination (home vs. all other destinations). 
 Statistical Analysis 
 Patients were dichotomized in a PA group and a non-PA group. 
The PA group was compared with the non-PA group with regard 
to baseline variables and outcome parameters using Mann-Whit-
ney U, t and   2 tests where appropriate. Data were given as mean 
and standard deviation ( 8 SD) or median with interquartile range 
(IQR). 
 Results 
 Study Population, Utilization Rate, and Possible 
Adverse Events 
 Two-hundred and forty-nine out of 264 stroke patients 
(94.3%) treated in the rehabilitation unit participated in 
the study. Fifteen patients (5.7%) were excluded, because 
no data on PA or on outcome or on both were available. 
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The mean age of the study population was 73 years (SD 
11.6), and 139 (56%) patients were men. In 207 (83%) pa-
tients the stroke was ischemic. Intracerebral hemorrhag-
es were present in 37 of 249 (15%) patients and subarach-
noid hemorrhages in 5 (2%) patients.
 Ninety-seven out of 249 (39%) patients had PA, while 
152 (61%) patients were in the non-PA group. The latter 
included 10 patients with dopaminergic substances for 
parkinsonism or restless leg syndrome, 17 with acetyl-
cholinesterase inhibitors for dementia and 71 patients 
with SSRI or SNRI for depression. 
 In the PA group,  L -dopa was used in 63 (65%), acetyl-
cholinesterase inhibitors in 33 (34%), and SSRI in 31 
(32%) patients.  Figure 1 summarizes the frequency of 
substances used for PA. In 50 patients more than one 
agent was used.  L -Dopa followed by SSRI or vice versa was 
the most frequently used combination (i.e. 28 patients). 
 Aphasia (37 patients; 38%) and paresis (23 patients; 
24%) were the most common symptoms for which PA was 
primarily used. Details are shown in  figure 2 . 
 Patients with PA versus Those without PA  
 PA patients did not differ from non-PA patients in age 
(mean age: 74  8 10.0 vs. 73  8 12.5 years; p = 0.62), gen-
der ratio (61 vs. 53% males; p = 0.24) und stroke type 
(ischemic stroke: 85 vs. 82%; p = 0.49). However, com-
pared with non-PA patients, PA patients were more se-
verely affected at entry [median NIH Stroke Scale Score 
7 (IQR 9) vs. 4 (IQR 5); p  ! 0.001; median FIM total 58 
(IQR 51) vs. 85 (IQR 55); p = 0.01]. 
 None in the PA group and 5/152 (3.3%) non-PA pa-
tients died during in-hospital rehabilitation (p = 0.16).
 Adverse events possibly associated with PA occurred 
in 11 patients (11.4%). Adverse events included delirium 
or hallucinations [4 patients with  L -dopa (n = 2), meman-
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 Fig. 1. Agents used for PA of rehabilitation. 
Aphasia
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Neglect/extinction
Low impulse
Other
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22%
 Fig. 2. Distribution of symptoms for which PA was primarily 
used. Other symptoms included ataxia, dysphagia, dyslexia, ag-
nosia, disorientation, memory dysfunction, visual-spatial distur-
bances, impaired executive functions, and fatigue. 
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tine (n = 1), or acetylcholinesterase inhibitor (n = 1)]. Four 
patients had gastrointestinal symptoms: diarrhea in 2 pa-
tients who had  L -dopa (n = 1) or acetylcholinesterase in-
hibitor (n = 1) and nausea in 2 patients [ L -dopa (n = 1), 
acetylcholinesterase inhibitor (n = 1)]. Electrolyte dis-
orders occurred in 2 patients who had hyponatremia at-
tributable to the use of SSRI. Incontinence occurred in
1 patient with an acetylcholinesterase inhibitor. In all
the aforementioned patients symptoms improved and 
eventually resolved after PA was stopped. None of the ad-
verse events was life-threatening or prolonged the length 
of stay in the rehabilitation unit.
 At discharge the PA group had a greater gain in func-
tionality, i.e. a higher median   FIM of 16 (IQR 27) as 
compared with non-PA patients and a median   FIM of 9 
(IQR 21) (p = 0.01). The secondary outcome measure, 
FIM efficacy, did not differ between both groups. Com-
parisons between patients with and without PA are sum-
marized in  table 1 .
 Discussion 
 This prospective explorative study revealed the fol-
lowing main findings. PA of stroke rehabilitation (1) was 
used frequently and (2) was tolerated well.
 More than one third of the patients treated in our 
stroke rehabilitation unit had PA. Thus, unlike in several 
controlled studies  [3, 6, 9, 14] , PA is not necessarily re-
stricted to highly selected subgroups of stroke patients. In 
fact, PA might be an adjunctive therapeutic option for 
several stroke patients during in-hospital rehabilitation. 
 L -Dopa, acetylcholinesterase inhibitors, and SSRI 
were used most frequently. For all these substances there 
are randomized controlled studies supporting their po-
tential benefit. For  L -dopa applied in addition to physio-
therapy, improvement of motor function (as quantified 
with the Rivermead motor assessment) has been shown 
as compared with physiotherapy alone  [3] . For acetylcho-
linesterase inhibitors, donezepil improved the severity of 
Table 1.  Baseline and outcome characteristics of patients with versus without PA of stroke rehabilitation
(n = 249)
Clinical characteristics With PA
(n = 97; 100%)
Without PA
(n = 152; 100%)
p value
Demographic data
Age (mean8 SD), years 74810.0 73812.6 0.62
Male sex, % (n) 61 (59) 53 (80) 0.24
Type of stroke
Ischemic strokes, % (n) 85 (82) 82 (125) 0.49
Stroke severity, at entry into rehab
Median NIHSS score (IQR) 
Median FIM (total) (IQR)
7 (9)
58 (51)
4 (5)
85 (55)
<0.001c
0.01c
Length of stay in rehab unit (median), days 48 (37) 28 (26) <0.001c
Death during in-hospital rehab, % (n) 0 3.3 (5) 0.16
Vascular risk factors, %
Hypertension 80 79 0.87
Smoking (current) 16 17 0.86
Hypercholesterolemia 43 57 0.35
Family history of stroke 11 10.5 0.80
Diabetes mellitus 23 27 0.55
Atrial fibrillation 29 25 0.37
Outcome at discharge
FIMa, median (IQR) 16 (27) 9 (21) 0.01c
FIM (total), median (IQR) 94 (41) 102 (33) 0.01c
FIM efficacyb, median (IQR) 29 (35) 31 (37) 0.47c
Discharge destination home (vs. all others), % (n) 54 (52) 70 (107) 0.01
a  FIM is a measure of the gain in functional abilities in activities of daily living. FIM = FIM at discharge 
– FIM at entry into the rehabilitation unit. b FIM efficacy = [FIM/(126 – FIM at entry)] ! 100. c Mann-Whit-
ney U test.
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stroke-related aphasia as compared with the placebo 
group  [6] . For SSRI, escitalopram improved cognitive re-
covery in stroke patients (quantified by the total score of 
the Repeatable Battery for the Assessment of Neuropsy-
chological Status) as compared with patients without es-
citalopram  [24] . 
 In the current study, the PA group had a greater gain 
in functionality (i.e. a higher median   FIM) at discharge 
as compared with non-PA patients. While the aforemen-
tioned studies reported on beneficial effects of PA on spe-
cific domains (i.e. motor function, language, cognition), 
our observation adds to these findings that PA might re-
sult in an improved recovery of abilities in activities of 
daily living (as measured with the FIM). However, the 
sample size of each of the aforementioned studies (n = 53 
 [3] ; n = 26  [6] ; n = 129, with 43 on escitalopram treatment 
 [24] ) and the current study was small, and some results 
were not reproduced by others  [11, 14] , indicating the risk 
of chance findings. 
 PA was tolerated well in most patients in the current 
cohort. In about 1 in 10 patients adverse events occurred. 
None of these events were severe and all were temporary. 
In addition, none of the PA patients died. Thus, the agents 
used for PA seem relatively safe. None of our patients had 
piracetam or amphetamines, about the safety of which 
there is doubt  [16–18] .
 We are aware of several limitations. First, this explor-
ative study was not a randomized trial. In fact, treatment 
with PA was allocated solely to patients, who the treating 
physicians thought might benefit. Thus, an allocation 
bias in favor of the PA group is likely. Second, we did not 
record the use of agents with unfavorable effects on re-
covery (e.g. antiepileptic drugs, butyrophenones)  [30] . 
The presence of such agents might have been a confound-
ing variable, if their use was unbalanced between the PA 
and the non-PA group. Third, non-PA patients were less 
severely affected than PA patients. Thus, the maximally 
achievable gain was smaller for non-PA as compared with 
PA patients. Thus, the greater increase in   FIM among 
PA patients (compared with non-PA patients) might in 
part reflect a ceiling effect in the non-PA group. Fourth, 
we did not record the amount of rehabilitative therapy. 
Thus, we do not know whether therapy intensity was bal-
anced between the two groups. Fifth, a substantial subset 
of patients in the non-PA group actually had agents pos-
sibly augmenting rehabilitation for established indica-
tions (e.g. Parkinson’s disease, dementia). Sixth, we did 
record potential adverse events solely for the PA group 
but not for the non-PA group. In addition, we could not 
establish potential relationships between adverse events 
and comorbidities. Thus, a comparative analysis of ad-
verse events was not feasible. However, this limitation 
would result in a potential overestimation rather than in 
an underestimation of possibly PA-related adverse events.
 In conclusion, the beneficial effect on the primary out-
come measure, the absence of severe adverse events, and 
the low rate of minor adverse events suggest that there is 
scope for benefit from PA in stroke rehabilitation. A large 
randomized controlled trial seems feasible and ethically 
justified.  L -Dopa may be an appropriate agent for such a 
trial. Indeed, in the United Kingdom a multicenter ran-
domized double-blinded placebo-controlled trial about 
dopamine-augmented rehabilitation in stroke  [31] is 
planned. 
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